WASHINGTON, D.C. — In a move that signals a significant shift in federal healthcare financing, the Centers for Medicare & Medicaid Services (CMS) has finalized the 2027 Medicare Hospital Outpatient Prospective Payment System (OPPS) rule. The centerpiece of the new regulation is a drastic reduction in reimbursement rates for drugs acquired through the 340B Drug Pricing Program.
n
Effective January 1, 2027, Medicare will reduce reimbursement for 340B-acquired drugs from the current rate of Average Sales Price (ASP) plus 6% to ASP minus 28%. This represents a total reduction of 32% in drug payments to covered entities. While CMS initially proposed a deeper cut of ASP minus 33.4%, the final rule settled on the -28% figure to align more closely with the maximum allowed acquisition costs and to simplify future regulatory updates.
n
Main Facts: The $4.65 Billion Reallocation
n
The finalized rule is not merely a cost-cutting measure but a massive redistribution of funds within the Medicare system. Because of federal "budget neutrality" requirements, CMS is mandated to ensure that changes to payment rates do not increase or decrease total aggregate spending under the OPPS.
n
The Budget Neutrality Equation
n
To offset the estimated $4.65 billion reduction in drug spending, CMS has finalized a 7.5% across-the-board increase in payments for non-drug outpatient services. This means that while hospitals will lose revenue on the administration of 340B drugs, they—and their non-340B counterparts—will receive higher payments for surgeries, diagnostic tests, and other clinic visits.
n
Impact on Beneficiaries
n
The shift creates a complex financial reality for Medicare beneficiaries. CMS estimates that patients who utilize 340B drugs will see their out-of-pocket costs drop by a collective $1.1 billion in 2027, as their 20% coinsurance will be calculated based on a much lower drug price. However, these same beneficiaries, along with those who do not use 340B drugs, will face higher cost-sharing for general outpatient services due to the 7.5% payment hike.
n
Scope of Exemptions
n
The rule does not apply universally to all providers. To protect the most vulnerable rural and specialized institutions, CMS has exempted several categories from the 340B payment cuts:
n
- n
- Rural Sole Community Hospitals (SCHs): These are often the only source of acute care in a geographic region.
- Children’s Hospitals: Specialized facilities focusing on pediatric care.
- PPS-Exempt Cancer Hospitals: Institutions dedicated exclusively to oncology treatment and research.
- Critical Access Hospitals (CAHs): These hospitals, which comprise the majority of rural facilities, are not reimbursed under the OPPS and are therefore unaffected.
n
n
n
n
n
Chronology: A Decade of Legal and Regulatory Volatility
n
The 2027 rule is the latest chapter in a long-standing battle between the federal government and the hospital industry over the 340B program, which was established in 1992 to help "stretch scarce federal resources as far as possible."
n
- n
- 2018: The first Trump administration implemented a similar cut, reducing 340B reimbursement to ASP minus 22.5%. The administration argued that hospitals were profiting excessively from the program rather than passing savings to patients.
- 2022: The U.S. Supreme Court, in American Hospital Association v. Becerra, unanimously overturned the 2018 cuts. The Court ruled that CMS could not vary reimbursement rates for specific groups of hospitals (like 340B entities) without first conducting a formal survey of hospital acquisition costs.
- Early 2026: In direct response to the Supreme Court’s mandate, CMS conducted a comprehensive cost acquisition survey of 340B drugs. The data from this survey provided the legal and empirical foundation for the current 2027 rule.
- July 2026: CMS released a revised rebate model pilot program, attempting to change how discounts are processed, though this remains embroiled in litigation.
- November 2026: CMS officially finalized the 2027 OPPS rule, setting the new reimbursement rate at ASP minus 28%.
n
n
n
n
n
n
Supporting Data: Winners and Losers by Hospital Type
n
The financial impact of the 2027 rule varies significantly based on a hospital’s business model and patient mix. According to CMS estimates, the redistribution of $4.65 billion will create distinct groups of financial winners and losers.
n
Safety-Net and Urban Hospitals
n
Safety-net hospitals, which are highly reliant on 340B drug margins to fund uncompensated care and social services, are expected to see a net decrease in Medicare revenue. Large urban teaching hospitals, which often dispense high volumes of expensive specialty drugs, will also face significant revenue contractions.
n
For-Profit and Non-340B Institutions
Conversely, for-profit hospitals and private outpatient centers that do not participate in the 340B program stand to benefit. Because these facilities do not lose revenue from the 340B cuts but do receive the 7.5% increase for general outpatient services, their total Medicare margins are projected to rise.
Comparative Operating Margins
Recent data from MedPAC and the 2026 Data Book highlight a growing disparity:
- Safety-Net Hospitals: Frequently operate with lower-than-average or negative operating margins.
- For-Profit Hospitals: Historically maintain much higher operating margins than the national average.
- Medicaid Dependency: Safety-net hospitals are also bracing for the impact of the 2025 reconciliation law, which is projected to reduce federal Medicaid spending, further tightening their financial outlook.
Official Responses: Diverging Perspectives
The finalization of the rule has reignited a fierce debate among healthcare stakeholders, reflecting the fundamental disagreement over the 340B program’s modern evolution.
The CMS Position
CMS officials have defended the rule as a necessary step toward market efficiency. "This change better aligns Medicare reimbursement with the actual costs hospitals incur when acquiring 340B drugs," the agency stated in its filing. CMS argues that the previous "ASP plus 6%" model provided an unintended windfall for hospitals, incentivizing them to acquire physician practices and move care into more expensive hospital settings to capture 340B spreads.
Hospital Advocacy Groups
Organizations such as the American Hospital Association (AHA) and 340B Health have expressed deep concern. They argue that the "savings" generated by the 340B program are not "excess profit" but are essential funds used to provide free clinics, transportation for patients, and subsidized pharmacy programs. Critics of the rule argue that by cutting these payments, CMS is effectively defunding the healthcare safety net.
Pharmaceutical Industry and Policy Reformers
Drug manufacturers and certain policy think tanks have supported the move toward transparency and cost-alignment. They contend that the 340B program has grown far beyond its original intent and that the lack of transparency regarding how hospitals spend their 340B savings has led to abuse. Some lawmakers have proposed legislative options to either narrow the scope of the program or require rigorous reporting on how 340B revenue is utilized.
Implications: A New Era of Healthcare Consolidation and Transparency
The 2027 rule will likely have far-reaching consequences for the structure of the U.S. healthcare delivery system.
Potential for Market De-consolidation
One of the primary criticisms of the 340B program was that it incentivized "vertical consolidation"—hospitals buying up independent oncology and rheumatology practices to gain 340B status for those locations. With the reimbursement rate dropping to ASP minus 28%, the financial incentive for these acquisitions may diminish, potentially slowing the trend of hospital-led consolidation.
State-Level Transparency Initiatives
As the federal government tightens reimbursement, states are increasingly stepping in to regulate 340B. Following the lead of Minnesota, several states are considering or have implemented laws requiring hospitals to disclose the exact amount of savings generated from the 340B program and, crucially, how those funds are reinvested into the community.
The Future of the Rebate Model
The ongoing legal battle over the "340B Rebate Model" remains a wildcard. If the courts eventually allow pharmaceutical companies to move from a "discount at point-of-sale" model to a "post-sale rebate" model, the administrative burden on hospitals could increase further. The Trump administration’s revised pilot program, currently under judicial review, could fundamentally alter the cash flow of 340B entities.
Financial Strain on Vulnerable Populations
The most pressing concern for policymakers remains the impact on the patients the 340B program was designed to serve. While some beneficiaries will see lower costs at the pharmacy counter, the overall reduction in hospital revenue could lead to the closure of service lines—such as behavioral health or maternal care—that are traditionally cross-subsidized by 340B earnings.
In conclusion, the 2027 Medicare OPPS rule represents a definitive pivot by CMS to exert more control over 340B spending. As the healthcare industry prepares for the January 1 implementation, the focus will shift to how safety-net hospitals adapt their business models to survive in a significantly leaner reimbursement environment.
